Bucephalus 📊

Setting the Scene

• In the United States, retailers are sitting on billions in unsold goods, with poor inventory management posing significant risks to companies.

  • Oversupply leads to inventory waste and capital being locked up.

  • Undersupply results in lost revenue, as customers switch products or brands rather than waiting for a restock.

• This week’s company provides an Al platform poised to overhaul outdated supply chain systems used by retailers and CPG brands.

In a Sentence

Bucephalus is an AI-driven platform replacing outdated ERPs to automate data-driven decision making and optimize supply chain planning.

• Platform: Bucephalus leverages genAI and predictive artificial intelligence to extract signals from emails, PDFs, and operational data to proactively manage inventory.

• ERP: Enterprise Resource Planning systems are centralized solutions that integrate and manage core business processes and data across sales, logistics, and financials.

• Optimize: Bucephalus enables retailers to scale faster with existing resources, increasing sell-through rates, minimizing costs, and enhancing operational adaptability.

The Basics

• Industry: Supply Chain Management, B2B SaaS, AI

• Headquarters: New York

• Year Founded: 2023

• Employee Count: 4

• Investors: Techstars, Textbook Ventures, Jerry Neumann, Amazon Leadership Syndicate

• Amount Raised: $450k in pre-seed funding

• Business Model: SaaS

• Early Traction: Dataset of 10M SKUs along with billions in transactions and inventory from free dashboard tool, advanced in 5 RFP processes for multibillion dollar brands

IN PARTNERSHIP WITH

• Over 130,000+ business and policy leaders read The Peak to stay up-to-date on critical news.

• With The Peak’s newsletters, podcasts, and their live events, you'll never miss an important moment!

Due Diligence

WHAT WE LIKE

• Market Opportunity: Bucephalus targets a significant supply chain management market with the potential to revolutionize how retailers and CPG brands operate by transitioning them from outdated systems to advanced AI-driven platforms.

• Bottomline Impact: Retailers lose 4-10% of potential revenue to stock-outs and 6% due to overstock.

  • Bucephalus helps mitigate these losses and boost customers' free cash flows through precise demand forecasting and optimized inventory management.

• Advanced AI: Bucephalus integrates a cutting-edge semantic data layer, transformer forecasting, and reinforcement learning, combining insights and actions into a cohesive platform far beyond a simple wrapper around existing AI tools.

POTENTIAL RISKS

• Market Penetration: Establishing credibility with large enterprises is challenging and requires robust case studies and pilot projects.

• Chicken and Egg: Some companies won’t commit to using Bucephalus without proof of a certain amount of capital in the bank to ensure the company’s longevity.

• Long Sales Cycles: The sales process with multibillion-dollar companies can be lengthy, potentially delaying revenue and requiring substantial resources to nurture leads and close deals.

Founder Profile

• Nick DeGiacomo, CEO: Previously led data science initiatives at Amazon's Supply Chain Optimization Technologies (SCOT) team.

• Jason Morganson, CTO: Previously VP of engineering at Cherre.

Comps

• Syrup: Backed by Accel & Google Ventures

• Nominal.so: Backed by Hyperwise Ventures, Bling Capital, Incubate Fund, Vela Partners

• Prediko: Backed by Techstars

• Blue Yonder: Backed by Blackstone, New Mountain Capital, Panasonic 

Upcoming Events

If you haven’t already signed up, we’d like to invite you to join us next week in NYC for a unique event designed to connect founders with funders.

Expect to meet amazing people and enjoy drinks, food, and music. Attendees will also leave with plenty of content to post about, whether it's from a live interview or the photo opportunity where each founder can submit their company logo to be featured on a massive billboard at the center of the venue.

Cast Your Vote

Last Week Today

• The results are in: Suji, a company that provides hardware to strengthen muscle groups, accelerate recovery, and relieve MSK, was favored in last week’s poll.

• Subscriber feedback: “Suji has the unique opportunity to capitalize on sports medicine by leveraging the huge market of people suffering from MSK.”